Exact Sciences Corporation Logo

Exact Sciences Corporation

EXAS

(0.5)
Stock Price

70,83 USD

-13.18% ROA

-6.6% ROE

-44.46x PER

Market Cap.

12.556.415.500,00 USD

153.6% DER

0% Yield

-8.17% NPM

Exact Sciences Corporation Stock Analysis

Exact Sciences Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Exact Sciences Corporation Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

2 ROE

The stock's ROE indicates a negative return (-9.19%) on shareholders' equity, suggesting poor financial performance.

3 ROA

The stock's ROA (-13.18%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

4 PBV

The stock's high Price-to-Book Value (P/BV) ratio (3.84x) suggests it's overvalued, potentially making it an expensive investment.

5 DER

The stock is burdened with a heavy load of debt (154%), making it financially unstable and potentially risky for investors.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-1.470) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Exact Sciences Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Exact Sciences Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Exact Sciences Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Exact Sciences Corporation Revenue
Year Revenue Growth
1998 0
1999 0 0%
2000 1 100%
2001 50.870 100%
2002 897.000 94.33%
2003 2.901.000 69.08%
2004 4.935.000 41.22%
2005 4.250.000 -16.12%
2006 4.750.000 10.53%
2007 2.935.000 -61.84%
2008 -867.000 438.52%
2009 4.758.000 118.22%
2010 5.344.000 10.97%
2011 4.163.000 -28.37%
2012 4.144.000 -0.46%
2013 4.144.000 0%
2014 1.798.000 -130.48%
2015 39.437.000 95.44%
2016 99.376.000 60.32%
2017 265.989.000 62.64%
2018 454.462.000 41.47%
2019 876.293.000 48.14%
2020 1.491.391.000 41.24%
2021 1.767.087.000 15.6%
2022 2.084.279.000 15.22%
2023 2.513.352.000 17.07%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Exact Sciences Corporation Research and Development Expenses
Year Research and Development Expenses Growth
1998 2.849.000
1999 3.688.796 22.77%
2000 5.332.055 30.82%
2001 13.335.265 60.02%
2002 19.989.000 33.29%
2003 17.084.000 -17%
2004 10.901.000 -56.72%
2005 7.843.000 -38.99%
2006 6.735.000 -16.45%
2007 4.887.000 -37.81%
2008 2.034.000 -140.27%
2009 4.213.000 51.72%
2010 9.023.000 53.31%
2011 21.968.000 58.93%
2012 42.131.000 47.86%
2013 27.678.000 -52.22%
2014 28.669.000 3.46%
2015 33.914.000 15.47%
2016 33.473.000 -1.32%
2017 42.139.000 20.57%
2018 68.210.000 38.22%
2019 139.694.000 51.17%
2020 554.052.000 74.79%
2021 385.646.000 -43.67%
2022 393.418.000 1.98%
2023 445.784.000 11.75%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Exact Sciences Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 12.866.062 100%
2002 11.744.000 -9.55%
2003 14.633.000 19.74%
2004 12.742.000 -14.84%
2005 10.849.000 -17.45%
2006 10.702.000 -1.37%
2007 8.532.000 -25.43%
2008 6.469.000 -31.89%
2009 9.510.000 31.98%
2010 6.330.000 -50.24%
2011 8.137.000 22.21%
2012 9.900.000 17.81%
2013 13.649.000 27.47%
2014 30.435.000 55.15%
2015 57.950.000 47.48%
2016 76.898.000 24.64%
2017 109.040.000 29.48%
2018 178.293.000 38.84%
2019 352.453.000 49.41%
2020 481.716.000 26.83%
2021 801.262.000 39.88%
2022 737.304.000 -8.67%
2023 869.572.000 15.21%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Exact Sciences Corporation EBITDA
Year EBITDA Growth
1998 -4.021.000
1999 -4.838.659 16.9%
2000 -6.557.574 26.21%
2001 -25.082.148 73.86%
2002 -28.687.000 12.57%
2003 -28.838.000 0.52%
2004 -19.195.000 -50.24%
2005 -14.382.000 -33.47%
2006 -12.825.000 -12.14%
2007 -10.493.000 -22.22%
2008 -8.143.000 -28.86%
2009 -9.214.000 11.62%
2010 -11.840.000 22.18%
2011 -28.412.000 58.33%
2012 -52.380.000 45.76%
2013 -46.445.000 -12.78%
2014 -100.539.000 53.8%
2015 -159.068.000 36.79%
2016 -169.016.000 5.89%
2017 -118.310.000 -42.86%
2018 -159.471.000 25.81%
2019 -217.747.000 26.76%
2020 -464.955.000 53.17%
2021 -740.467.000 37.21%
2022 -480.092.000 -54.23%
2023 119.364.000 502.21%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Exact Sciences Corporation Gross Profit
Year Gross Profit Growth
1998 0
1999 0 0%
2000 404.143 100%
2001 50.870 -694.46%
2002 888.000 94.27%
2003 2.879.000 69.16%
2004 4.448.000 35.27%
2005 3.684.000 -20.74%
2006 3.941.000 6.52%
2007 1.749.000 -125.33%
2008 -868.000 301.5%
2009 4.738.000 118.32%
2010 5.320.000 10.94%
2011 4.139.000 -28.53%
2012 4.144.000 0.12%
2013 4.144.000 0%
2014 -2.527.000 263.99%
2015 14.936.000 116.92%
2016 54.181.000 72.43%
2017 186.793.000 70.99%
2018 336.480.000 44.49%
2019 659.576.000 48.99%
2020 1.137.067.000 41.99%
2021 1.308.330.000 13.09%
2022 1.509.885.000 13.35%
2023 1.839.248.000 17.91%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Exact Sciences Corporation Net Profit
Year Net Profit Growth
1998 -3.578.000
1999 -4.963.925 27.92%
2000 -11.883.119 58.23%
2001 -23.485.425 49.4%
2002 -29.883.000 21.41%
2003 -28.340.000 -5.44%
2004 -18.523.000 -53%
2005 -14.520.000 -27.57%
2006 -12.915.000 -12.43%
2007 -11.959.000 -7.99%
2008 -9.741.000 -22.77%
2009 -9.089.000 -7.17%
2010 -11.556.000 21.35%
2011 -28.675.000 59.7%
2012 -52.421.000 45.3%
2013 -46.514.000 -12.7%
2014 -100.048.000 53.51%
2015 -157.803.000 36.6%
2016 -167.211.000 5.63%
2017 -114.397.000 -46.17%
2018 -175.149.000 34.69%
2019 -83.993.000 -108.53%
2020 -848.533.000 90.1%
2021 -595.625.000 -42.46%
2022 -623.506.000 4.47%
2023 3.176.000 19731.8%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Exact Sciences Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 -6
1999 -5 -20%
2000 -8 37.5%
2001 -1 -700%
2002 -2 0%
2003 -2 0%
2004 -1 0%
2005 -1 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 -1 0%
2012 -1 0%
2013 -1 0%
2014 -1 100%
2015 -2 0%
2016 -2 0%
2017 -1 0%
2018 -1 100%
2019 -1 0%
2020 -6 100%
2021 -3 -66.67%
2022 -4 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Exact Sciences Corporation Free Cashflow
Year Free Cashflow Growth
1999 -4.899.780
2000 -8.754.063 44.03%
2001 -18.451.983 52.56%
2002 -13.252.000 -39.24%
2003 -24.879.000 46.73%
2004 -21.461.000 -15.93%
2005 -16.209.000 -32.4%
2006 -12.548.000 -29.18%
2007 -8.899.000 -41%
2008 -8.008.000 -11.13%
2009 -13.102.000 38.88%
2010 -14.104.000 7.1%
2011 -29.939.000 52.89%
2012 -44.836.000 33.23%
2013 -48.577.000 7.7%
2014 -93.449.000 48.02%
2015 -156.001.000 40.1%
2016 -144.917.000 -7.65%
2017 -140.964.000 -2.8%
2018 -219.996.000 35.92%
2019 -286.812.000 23.3%
2020 72.130.000 497.63%
2021 -238.002.000 130.31%
2022 -438.021.000 45.66%
2023 -826.000 -52929.18%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Exact Sciences Corporation Operating Cashflow
Year Operating Cashflow Growth
1999 -4.607.597
2000 -7.991.416 42.34%
2001 -15.836.584 49.54%
2002 -11.917.000 -32.89%
2003 -13.870.000 14.08%
2004 -21.174.000 34.5%
2005 -15.982.000 -32.49%
2006 -12.154.000 -31.5%
2007 -8.767.000 -38.63%
2008 -7.904.000 -10.92%
2009 -12.640.000 37.47%
2010 -13.478.000 6.22%
2011 -27.824.000 51.56%
2012 -44.155.000 36.99%
2013 -39.295.000 -12.37%
2014 -80.912.000 51.43%
2015 -134.017.000 39.63%
2016 -130.066.000 -3.04%
2017 -71.724.000 -81.34%
2018 -69.325.000 -3.46%
2019 -115.010.000 39.72%
2020 136.482.000 184.27%
2021 -102.236.000 233.5%
2022 -223.559.000 54.27%
2023 24.361.000 1017.69%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Exact Sciences Corporation Capital Expenditure
Year Capital Expenditure Growth
1999 292.183
2000 762.647 61.69%
2001 2.615.399 70.84%
2002 1.335.000 -95.91%
2003 11.009.000 87.87%
2004 287.000 -3735.89%
2005 227.000 -26.43%
2006 394.000 42.39%
2007 132.000 -198.48%
2008 104.000 -26.92%
2009 462.000 77.49%
2010 626.000 26.2%
2011 2.115.000 70.4%
2012 681.000 -210.57%
2013 9.282.000 92.66%
2014 12.537.000 25.96%
2015 21.984.000 42.97%
2016 14.851.000 -48.03%
2017 69.240.000 78.55%
2018 150.671.000 54.05%
2019 171.802.000 12.3%
2020 64.352.000 -166.97%
2021 135.766.000 52.6%
2022 214.462.000 36.69%
2023 25.187.000 -751.48%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Exact Sciences Corporation Equity
Year Equity Growth
1998 9.298.000
1999 4.410.015 -110.84%
2000 27.699.808 84.08%
2001 58.966.805 53.02%
2002 38.349.000 -53.76%
2003 12.228.000 -213.62%
2004 37.983.000 67.81%
2005 24.621.000 -54.27%
2006 14.958.000 -64.6%
2007 6.288.000 -137.88%
2008 -2.433.000 358.45%
2009 6.133.000 139.67%
2010 79.754.000 92.31%
2011 83.495.000 4.48%
2012 98.595.000 15.32%
2013 135.316.000 27.14%
2014 288.984.000 53.18%
2015 326.856.000 11.59%
2016 335.295.000 2.52%
2017 520.418.000 35.57%
2018 680.941.000 23.57%
2019 2.288.061.000 70.24%
2020 2.823.489.000 18.96%
2021 3.387.636.000 16.65%
2022 3.043.162.000 -11.32%
2023 3.121.227.000 2.5%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Exact Sciences Corporation Assets
Year Assets Growth
1998 9.708.000
1999 4.753.903 -104.21%
2000 29.058.502 83.64%
2001 63.100.237 53.95%
2002 50.086.000 -25.98%
2003 34.681.000 -44.42%
2004 56.111.000 38.19%
2005 37.845.000 -48.27%
2006 23.868.000 -58.56%
2007 14.595.000 -63.54%
2008 5.898.000 -147.46%
2009 25.770.000 77.11%
2010 96.515.000 73.3%
2011 96.953.000 0.45%
2012 112.119.000 13.53%
2013 146.627.000 23.53%
2014 311.624.000 52.95%
2015 364.296.000 14.46%
2016 377.040.000 3.38%
2017 598.560.000 37.01%
2018 1.524.022.000 60.72%
2019 3.505.768.000 56.53%
2020 4.925.092.000 28.82%
2021 6.684.884.000 26.32%
2022 6.226.873.000 -7.36%
2023 6.420.830.000 3.02%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Exact Sciences Corporation Liabilities
Year Liabilities Growth
1998 410.000
1999 343.888 -19.22%
2000 1.358.694 74.69%
2001 4.133.432 67.13%
2002 11.737.000 64.78%
2003 22.453.000 47.73%
2004 18.128.000 -23.86%
2005 13.224.000 -37.08%
2006 8.910.000 -48.42%
2007 8.307.000 -7.26%
2008 8.331.000 0.29%
2009 19.637.000 57.57%
2010 16.761.000 -17.16%
2011 13.458.000 -24.54%
2012 13.524.000 0.49%
2013 11.311.000 -19.57%
2014 22.640.000 50.04%
2015 37.440.000 39.53%
2016 41.745.000 10.31%
2017 78.142.000 46.58%
2018 843.081.000 90.73%
2019 1.217.707.000 30.76%
2020 2.101.603.000 42.06%
2021 3.297.248.000 36.26%
2022 3.183.711.000 -3.57%
2023 3.299.603.000 3.51%

Exact Sciences Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
13.32
Net Income per Share
-1.56
Price to Earning Ratio
-44.46x
Price To Sales Ratio
5.22x
POCF Ratio
90.49
PFCF Ratio
-533.48
Price to Book Ratio
4.02
EV to Sales
6
EV Over EBITDA
-84.63
EV to Operating CashFlow
104.2
EV to FreeCashFlow
-613.63
Earnings Yield
-0.02
FreeCashFlow Yield
-0
Market Cap
12,56 Bil.
Enterprise Value
14,44 Bil.
Graham Number
24.64
Graham NetNet
-13

Income Statement Metrics

Net Income per Share
-1.56
Income Quality
-0.49
ROE
-0.09
Return On Assets
-0.03
Return On Capital Employed
-0.04
Net Income per EBT
1.01
EBT Per Ebit
0.94
Ebit per Revenue
-0.09
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0.36
Research & Developement to Revenue
0.17
Stock Based Compensation to Revenue
0.04
Gross Profit Margin
0.74
Operating Profit Margin
-0.09
Pretax Profit Margin
-0.08
Net Profit Margin
-0.08

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.77
Free CashFlow per Share
-0.13
Capex to Operating CashFlow
-1.17
Capex to Revenue
-0.07
Capex to Depreciation
-1.08
Return on Invested Capital
-0.03
Return on Tangible Assets
-0.13
Days Sales Outstanding
30.25
Days Payables Outstanding
42.65
Days of Inventory on Hand
77.02
Receivables Turnover
12.07
Payables Turnover
8.56
Inventory Turnover
4.74
Capex per Share
-0.9

Balance Sheet

Cash per Share
4,07
Book Value per Share
17,28
Tangible Book Value per Share
-6.41
Shareholders Equity per Share
17.28
Interest Debt per Share
26.67
Debt to Equity
1.54
Debt to Assets
0.75
Net Debt to EBITDA
-11.06
Current Ratio
2.41
Tangible Asset Value
-1,16 Bil.
Net Current Asset Value
-2,15 Bil.
Invested Capital
1.54
Working Capital
0,67 Bil.
Intangibles to Total Assets
0.67
Average Receivables
0,19 Bil.
Average Payables
0,07 Bil.
Average Inventory
131805500
Debt to Market Cap
0.38

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Exact Sciences Corporation Dividends
Year Dividends Growth

Exact Sciences Corporation Profile

About Exact Sciences Corporation

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

CEO
Mr. Kevin T. Conroy
Employee
6.500
Address
5505 Endeavor Lane
Madison, 53719

Exact Sciences Corporation Executives & BODs

Exact Sciences Corporation Executives & BODs
# Name Age
1 Mr. James Herriott
Senior Vice President, General Counsel & Secretary
70
2 Ms. Sarah Condella
Executive Vice President of Human Resources
70
3 Dr. Jorge A. Garces Ph.D.
Chief Science Officer
70
4 Mr. Kevin T. Conroy
Chairman of The Board & Chief Executive Officer
70
5 Mr. Tim Caprez
Chief Compliance Counsel & Vice President
70
6 Mr. Jeffrey T. Elliott CFA
EVice President & Chief Financial Officer
70
7 Mr. Vic Parker
Head of Sales
70
8 Ms. Megan Jones
Associate Manager of Investor Relations
70
9 Mr. Nassar Nizami
Chief Information Officer
70
10 Mr. Everett V. Cunningham
Chief Commercial Officer
70

Exact Sciences Corporation Competitors